EGFR and malignant colon neoplasm: Although the rectum is routinely grouped in the left-sided colon in current treatment guidelines, this large-scale retrospective study, nevertheless, demonstrates that anti-EGFR therapy has lower efficacy in metastatic middle/low rectal cancer than in left-sided colon cancer, potentially leading to better clinical practice principles for mCRC management.